Key result
LVAD placement treats cardiogenic shock in a 35-year-old woman with mitochondrial cardiomyopathy and high lactate.
Why the study?
Mitochondrial cardiomyopathy in adults is a diagnostic and therapeutic challenge with unknown outcomes after LVAD placement.
Case Report (n=1)
Mitochondrial cardiomyopathy can present as cardiogenic shock and be managed with LVAD, though it may be complicated by right ventricular failure.
LVAD may be feasible in mitochondrial cardiomyopathy with shock despite RV failure risk; leaves open optimal selection and durable support strategies.
Background: Mitochondrial cardiomyopathy (MCM) is an alteration in cardiac structure and function caused by gene mutations or deletions affecting components of the mitochondrial respiratory chain. We report a case of MCM presenting as cardiogenic shock, ultimately requiring left ventricular assist device (LVAD) placement. Case summary: A 35-year-old woman with chronic weakness and non-ischaemic cardiomyopathy, on home dobutamine, was referred to our institution for heart transplantation evaluation. She was admitted to the hospital for suspected cardiogenic shock after laboratory tests revealed a lactate level of 5.4 mmol/L (ref: 0.5-2.2 mmol/L). Her hospital course was complicated by persistently undulating lactate levels (0.2-8.6 mmol/L) that increased with exertion and did not correlate with mixed venous oxygen saturation measurements obtained from a pulmonary artery catheter. Electrodiagnostic testing demonstrated a proximal appendicular and axial myopathy. A left deltoid muscle biopsy was performed that demonstrated evidence of a mitochondrial disease on light and electron microscopy. Muscle genetic testing revealed two large-scale mitochondrial deoxyribonucleic acid sequence deletions, confirming the diagnosis of MCM. She subsequently underwent LVAD placement, which was complicated by significant right ventricular failure requiring early mechanical support. She was ultimately discharged home with chronic inotropic support. Discussion: Mitochondrial cardiomyopathy in adults is a diagnostic and therapeutic challenge. Prompt diagnosis should be made in patients with unknown causes of heart failure via skeletal muscle histopathology guided by electrodiagnostic studies, and targeted genetic testing in affected tissue. Outcomes in adult MCM patients who receive an LVAD are unknown and warrant further investigation.
No takes yet. Share an insight, caveat, or question.
Girard et al. (2023) conducted a case report in Mitochondrial cardiomyopathy presenting as cardiogenic shock (n=1). Left ventricular assist device (LVAD) placement was evaluated. Left ventricular assist device placement was utilized to treat cardiogenic shock in a 35-year-old woman with mitochondrial cardiomyopathy and persistently undulating lactate levels up to 8.6 mmol/L.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: